Data Show PIK3CA Mutation Does Not Affect Breast Cancer Treatment Benefit With Alpelisib
June 3rd 2022Analysis shows that different genetic mutation profiles in tumors harboring PIK3CA mutation did not affect the treatment benefit with alpelisib (Piqray) combined with fulvestrant in individuals with HR+/HER2- advanced or metastatic breast cancer.
Read More
Co-Founder of House Rx Discusses The Company's Technology Platform and Pharmacy Service
June 2nd 2022Ogi Kavazovic, co-founder and CEO of House Rx, discusses the company's technology platform and pharmacy service and how it can better enable community oncology pharmacy practices to offer medically integrated dispensing.
Watch